干扰素ɑ-1b联合孟鲁司特钠治疗小儿呼吸道合胞病毒毛细支气管炎的临床研究  

Clinical research of interferonɑ-1b combined with montelukast sodium in the treatment of pediatric respiratory syncytial virus bronchiolitis

作　　者：杨婧婧 钟华文 赖志飞 赵渠 YANG Jingjing;ZHONG Huawen;LAI Zhifei(Department of Pediatrics,Fenggang Hospital,Dongguan 523690,China)

机构地区：[1]东莞市凤岗医院儿科,广东东莞523690

出　　处：《中国处方药》2025年第3期64-67,共4页Journal of China Prescription Drug

摘　　要：目的对呼吸道合胞病毒毛细支气管炎患儿给予干扰素ɑ-1b、孟鲁司特钠联合治疗,分析二者联合用药的临床效果。方法随机将2022年11月~2024年3月期间入组的70例呼吸道合胞病毒毛细支气管炎患儿分为对照组(35例,给予孟鲁司特钠治疗)、观察组(35例,给予干扰素ɑ-1b、孟鲁司特钠联合治疗)。对两组临床疗效、症状消失时间、生化指标[白细胞介素-6(IL-6)、中性粒细胞/淋巴细胞比值(NLR)]、不良反应和复发率进行对比。结果治疗7 d后,观察组治疗总有效率和对照组比较明显更高,且治疗期间观察组患儿症状(咳嗽、喘息、气促)消失时间较对照组更短(P<0.05)。治疗后,观察组IL-6、NLR水平和对照组相比均明显更低(P<0.05)。治疗期间,观察组不良反应总发生率为8.57%(3/35),对照组为14.29%(5/35),两组数据比较差异无统计学意义(P>0.05)。对两组患儿进行6个月时间的规律随访,观察组治疗后3个月的呼吸道合胞病毒毛细支气管炎复发率低于对照组(0.00%vs.14.29%,P<0.05),但治疗后6个月的复发率和对照组比较差异无统计学意义(8.57%vs.20.00%,P>0.05)。结论对呼吸道合胞病毒毛细支气管炎患儿给予干扰素ɑ-1b、孟鲁司特钠联合治疗的有效性和安全性较好,能有效缩短症状消失时间,降低炎症指标和近期复发风险。Objective To explore the clinical efficacy of interferonɑ-1b combined with montelukast sodium in the treatment of pediatric respiratory syncytial virus bronchiolitis.Methods Seventy children with respiratory syncytial virus bronchiolitis treated from November 2022 to March 2024 were randomly divided into the control group(35 cases,treated with montelukast sodium)and the observation group(35 cases,treated with interferonɑ-1b and montelukast sodium combination therapy).Compare the clinical efficacy,symptom disappearance time,biochemical indicators[Interleukin-6(IL-6),neutrophil/lymphocyte ratio(NLR)],adverse reactions and recurrence rates between two groups.Results After 7 days of treatment,the total effective rate of the observation group was significantly higher than that of the control group,and the disappearance time of symptoms(cough,wheezing,shortness of breath)in the observation group was shorter than that of the control group during the treatment period(P<0.05).Compared with the control group,the observation group had lower levels of IL-6 and NLR after treatment(P<0.05).During the treatment period,there was no significant difference in adverse reaction data between the two groups(P>0.05),with the observation group accounting for 8.57%(3/35)and the control group accounting for 14.29%(5/35).Two groups of children were followed up regularly for 6 months.The observation group had a lower recurrence rate of respiratory syncytial virus bronchiolitis than the control group at 3 months after treatment(0.00%vs.14.29%,P<0.05),but the recurrence rate at 6 months after treatment was not significantly different compared with the control group(8.57%vs.20.00%,P>0.05).Conclusion The combination of interferonα-1b and montelukast sodium has good efficacy and safety in the treatment of pediatric respiratory syncytial virus bronchiolitis.It can effectively shorten the time for symptoms to disappear,reduce inflammatory indicators and lower the risk of short-term recurrence.

关 键 词：干扰素ɑ-1b 孟鲁司特钠 呼吸道合胞病毒 毛细支气管炎 不良反应 

分 类 号：R725.6[医药卫生—儿科]